SCHEMBL19203471

SCHEMBL19203471

C[C@@H](CN)N(C)Cc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.69
ADRA2B P18089 2/20 0.69
ADRA2C P18825 2/20 0.69
ADRA1A P35348 2/20 0.69
OPRK1 P41145 2/20 0.69
SLC6A4 P31645 2/20 0.69
SLC6A3 Q01959 2/20 0.69
HTR2A P28223 1/20 0.69
KCNH2 Q12809 1/20 0.69
AOC3 Q16853 1/20 0.52
TSHR P16473 3/20 0.50
CARM1 Q86X55 1/20 0.50
PRMT6 Q96LA8 1/20 0.50
PRMT8 Q9NR22 1/20 0.50
ALDH1A1 P00352 1/20 0.50
SIGMAR1 Q99720 4/20 0.46
MAOB P27338 5/20 0.43
MAOA P21397 5/20 0.43
CYP1A2 P05177 2/20 0.43
ADRA2A P08913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10675561 1.00 SLC6A2 (0.69) SLC6A2ADRA2BADRA2CADRA1AOPRK1
Cadaverine Tartrate SCHEMBL30658440 0.87 ADRA2B (0.54) SLC6A2ADRA2BADRA2CADRA1AOPRK1
Cadaverine Tartrate SCHEMBL20702014 0.87 ADRA2B (0.54) SLC6A2ADRA2BADRA2CADRA1AOPRK1
SCHEMBL20237216 0.82 SLC6A2 (0.50) SLC6A2ADRA2BADRA2CADRA1AOPRK1
Benzphetamine SCHEMBL19285634 0.82 ADRA2B (1.00) SLC6A2ADRA2BADRA2CADRA1AOPRK1
SCHEMBL12658318 0.82 SLC6A2 (0.50) SLC6A2ADRA2BADRA2CADRA1AOPRK1
Benzphetamine SCHEMBL678807 0.82 ADRA2B (1.00) SLC6A2ADRA2BADRA2CADRA1AOPRK1
Benzphetamine SCHEMBL49120 0.82 ADRA2B (1.00) SLC6A2ADRA2BADRA2CADRA1AOPRK1
SCHEMBL15003030 0.82 ADRA2B (0.71) SLC6A2ADRA2BADRA2CADRA1AOPRK1
Benzphetamine SCHEMBL260091 0.80 ADRA2B (0.96) SLC6A2ADRA2BADRA2CADRA1AOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085060-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LTD (GB) 2026-03-26 US claimed
US-11753398-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2023-09-12 US disclosed
US-11753398-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2023-09-12 US disclosed
US-20210395227-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2021-12-23 US disclosed
US-11130746-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2021-09-28 US disclosed
US-20200255404-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2020-08-13 US disclosed
US-10696654-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2020-06-30 US disclosed
EP-3408265-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2020-05-13 EP disclosed
US-20190040041-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2019-02-07 US disclosed
WO-2017129829-A1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LIMITED (GB) 2017-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696654-B2 Therapeutic compounds HCRTR2, HCRTR1, NPY1R SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885
US-11753398-B2 Therapeutic compounds HCRTR2, HCRTR1, NPY1R SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885
US-20190040041-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885
US-11130746-B2 Therapeutic compounds HCRTR2, HCRTR1, NPY1R SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885
US-20200255404-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885
US-20210395227-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R SLC6A2 437/4885ADRA2B 200/4885ADRA2C 148/4885
US-20260085060-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R SLC6A2 317/4885ADRA2B 501/4885ADRA2C 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.